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Abstract The opportunistic mycopathogen Aspergillus fumiga-
tus expresses both glucosylceramide and galactosylceramide
(GlcCer and GalCer), but their functional signi¢cance in Asper-
gillus species is unknown. We here identi¢ed and characterized a
GlcCer from Aspergillus nidulans, a non-pathogenic model fun-
gus. Involvement of GlcCer in fungal development was tested
on both species using a family of compounds known to inhibit
GlcCer synthase in mammals. Two analogs, D-threo-1-phenyl-2-
palmitoyl-3-pyrrolidinopropanol (P4) and D-threo-3P,4P-ethyl-
enedioxy-P4, strongly inhibited germination and hyphal growth.
Neutral lipids from A. fumigatus cultured in the presence of
these inhibitors displayed a signi¢cantly reduced GlcCer/Gal-
Cer ratio. These results suggest that synthesis of GlcCer is
essential for normal development of A. fumigatus and
A. nidulans. - 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Investigations of glycosphingolipid (GSL) biosynthesis and
function in Saccharomyces cerevisiae and other fungi have
established that they are essential components of the fungal
cell membrane [1^3]. These studies have focused mainly on
glycosylinositol phosphorylceramides (GIPCs), a family of
compounds widely distributed among fungi but not found in
animal cells or tissues [4,5]. Unlike S. cerevisiae, however,
most fungi synthesize not only GIPCs, but also neutral mono-
hexosylceramides (also referred to as cerebrosides or CMHs).
It appears that the majority of fungi express glucosylceramide
(GlcCer) only, but some Euascomycetes, such as Aspergillus
fumigatus [6,7], Aspergillus niger [8], and Sporothrix schenckii
[9], also synthesize galactosylceramide (GalCer). The ceramide
moieties in fungal cerebrosides have a number of structural
features that distinguish them from those found in mamma-
lian GSLs, including (E)-v8 unsaturation and 9-methyl group
branching of the sphingoid base, and variable levels of (E)-v3
unsaturation of the fatty acid. In addition, they are di¡erent
from those found in fungal GIPCs, suggesting that they are
assembled from structurally distinct pools of sphingoid bases
[1,7].
Several putative GlcCer synthase (GCS; UDP-Glc:cera-
mide L-glucosyltransferase) gene homologs have appeared in
fungal genome databases. A number of these were cloned,
expressed, and their enzymatic function veri¢ed [10]. How-
ever, despite a number of studies demonstrating intriguing
physiological activities of endogenously added fungal cerebro-
sides [11^14], the true in vivo functions of these compounds
remain unclear. Structural analogs of D-threo-1-phenyl-2-dec-
anoylamino-3-morpholino-1-propanol (D-threo-PDMP) [15]
have been widely applied for inhibition of GCS in mammalian
cells [16^18], but no applications to fungi have been reported.
Recently, PDMP analogs have been generated exhibiting im-
proved speci¢city and potency, eliminating undesired e¡ects
encountered with the parent compound, such as ceramide
accumulation and resultant triggering of apoptosis [16,17].
The studies described in this paper demonstrate that some
PDMP analogs strongly a¡ect cerebroside biosynthesis in
A. fumigatus and Aspergillus nidulans, resulting in profound
physiological e¡ects.
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2. Materials and methods
2.1. GCS inhibitors
Inhibition studies were performed with D/L-threo-PDMP [15], and a
series of homologs and analogs of the active isomer D-threo-PDMP:
D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP)
[19], D-threo-1-phenyl-2-palmitoyl-3-pyrrolidinopropanol (PPPP or
P4) [16,17], and D-threo-3P,4P-ethylenedioxy-P4 (EDO-P4) [17].
2.2. Fungal isolates and culture conditions
A. fumigatus ATCC strain 9197 and A. nidulans FGSC strain A28
were used for most experiments. A. fumigatus strain 237, originally
cultured from open lung biopsy from a patient with invasive pulmo-
nary aspergillosis at Hope Hospital (Manchester, UK), was the gift of
Dr. David W. Holden (Hammersmith Hospital, London, UK). Ap-
proximately 1U109 spores were inoculated to 200 ml complete me-
dium (1% glucose, 0.2% peptone, 0.1% yeast extract, 0.1% casamino
acids, nitrate salts, trace elements, and 0.01% vitamins, pH 6.5; trace
elements, vitamins, nitrate salts, and amino acid supplements are de-
scribed in the appendix to Kafer [20]), incubated at 30 or 37‡C with
shaking (200 rpm) for 24 h, ¢ltered, and processed as described.
Yields were 3^10 g wet weight per 200 ml medium. For experiments
in which mycelia were grown in the presence of GCS inhibitors, in-
cubations were performed at 37‡C, and inhibitors were added from
70% ethanol stock solutions 6 h after inoculation.
2.3. Solvents for extraction, anion exchange chromatography, and
HPTLC
Solvent A, chloroform/methanol (1:1, v/v); solvent B, isopropanol/
hexane/water (55:25:20 v/v, upper phase discarded); solvent C, chlo-
roform/methanol/water (30:60:8 v/v); solvent D, chloroform/metha-
nol/2 N ammonium hydroxide (50:10:1 v/v); solvent E, isopropanol/
hexane/water (55:40:5 v/v).
2.4. Extraction, puri¢cation, and characterization of GSLs
Extraction and puri¢cation of GSLs were carried out as described
previously [7]. Brie£y, GSLs were extracted by homogenizing mycelia
(3^10 g wet weight) in an Omni-mixer (Sorvall, Wilmington, DE,
USA), once with 100 ml of solvent A, twice with 100 ml of solvent
B, and once more with 100 ml of solvent A. Between homogenization
steps, mycelia were collected by vacuum ¢ltration through a sintered
glass funnel. The four ¢ltrates were pooled, dried on a rotary evapo-
rator, dialyzed against water, lyophilized, resuspended in solvent C,
and applied to a column of DEAE-Sephadex A-25 (Ac3 form). Neu-
tral lipids containing CMHs were eluted with ¢ve volumes of solvent
C, dried down, and examined by high performance thin layer chro-
matography (HPTLC) as described below; where necessary, individ-
ual components were further puri¢ed by preparative-scale HPTLC as
previously described [21]. The purity and identity of each fraction
were assessed by analytical HPTLC, 1H-NMR spectroscopy, and pos-
itive ion mode electrospray ionization mass spectrometry (þESI-MS)
as described previously [7^9,21].
2.5. Analytical HPTLC
All HPTLC was performed on silica gel 60 plates (E. Merck, Darm-
stadt, Germany) using solvent D as mobile phase [21]. Samples were
dissolved in solvent E and applied by streaking from 10 Wl Micro-caps
(Drummond, Broomall, PA, USA). For analytical HPTLC, detection
was made by Bial’s orcinol reagent (orcinol 0.55% w/v and H2SO4
5.5% v/v in ethanol/water 9:1 v/v; the plate is sprayed and heated
brie£y to V200^250‡C).
2.6. Coverslip assays, staining and microscopy
The protocol of Harris et al. [22] was used for growth and staining
of A. fumigatus and A. nidulans as follows. Ten ml complete liquid
medium was inoculated with 1^5U104 conidia/ml, poured into a Petri
dish containing a glass coverslip, and incubated at 37‡C (in some
cases 30‡C) for the time indicated in each experiment. Where used,
GCS inhibitors were added at t=5 h after the start of incubation
unless otherwise noted. Coverslips with adhering germlings were ¢xed
in 3.7% formaldehyde, 50 mM phosphate bu¡er (pH 7.0) and 0.2%
Triton X-100 for 30^60 min. Coverslips were then washed with water,
incubated 5 min with 10 Wg/ml Calco£uor (Bayer, Leverkusen, Ger-
many) and 100 ng/ml Hoechst 33258 (Sigma), washed again and
mounted on a microscope slide for viewing. Germlings were observed
using a Zeiss Axioplan microscope and photographed using an Op-
tronics Digital Imaging System (Goleta, CA, USA).
2.7. Minimal inhibitory concentration experiments
Approximately 103 conidia were inoculated to 1 ml complete me-
dium, and inhibitors added from a concentrated stock in 70% ethanol.
Negative control samples contained an equivalent amount of 70%
ethanol. After incubation at 37‡C without agitation for 3 h, conidia
were washed twice in fresh complete medium, resuspended in com-
plete medium and plated. After 36 h incubation at 37‡C, colony form-
ing units were counted. The experiment was repeated twice with sim-
ilar results.
3. Results
3.1. Comparison of GlcCer and GalCer expression in
A. fumigatus and A. nidulans
It is known that A. fumigatus expresses both GlcCer and
GalCer, and these components have been thoroughly charac-
terized [6,7]. In the present work, we observed quantitative
variability of these components depending on strain and cul-
ture conditions, especially temperature. Two strains of A. fu-
migatus (9197 and 237) were cultured for 24 h at 30‡C or
37‡C, under otherwise identical conditions, and their total
neutral lipids compared by HPTLC analysis (Fig. 1, lanes
1^4). Bands corresponding to GlcCer and GalCer were re-
solved and identi¢ed by co-migration with standard com-
pounds previously isolated and characterized [7] (lanes S1,
S2, respectively). In both strains of A. fumigatus, the relative
amounts of GlcCer were elevated at 37‡C (lanes 2 and 4).
Since the GlcCer/GalCer ratio was observed to be highest
with A. fumigatus strain 9197 at 37‡C, subsequent experiments
with inhibitors were performed with this strain, and measure-
ments of GlcCer/GalCer ratios were carried out at 37‡C.
In A. nidulans, orcinol-positive bands corresponding in Rf
value to GlcCer were observed at both temperatures (Fig. 1,
lanes 5 and 6). Since GSLs of A. nidulans have never been
characterized, the putative GlcCer components from both cul-
ture temperatures were isolated by preparative HPTLC and
subjected to structural analysis by 1H-NMR and þESI-MS.
3.2. Characterization of A. nidulans cerebroside fractions
Both 1H- and 13C-NMR spectra for underivatized fungal
cerebrosides have been previously acquired and all resonances
assigned by homonuclear and heteronuclear 2-D correlation
Fig. 1. Comparison of GlcCer and GalCer expression in A. fumiga-
tus and A. nidulans showing temperature dependence. Lower section
of orcinol-stained analytical HPTLC plate compares crude neutral
lipids extracted from A. fumigatus strains 9197 (lanes 1,2) and 237
(lanes 3,4), and A. nidulans strain A28 (lanes 5,6). Mycelia were cul-
tured at 30‡C (lanes 1,3,5) or 37‡C (lanes 2,4,6). Lanes S1 and S2,
standards of GlcCer and GalCer from A. fumigatus strain 9197 pre-
viously characterized by NMR and þESI-MS [8]. Bracketed band
appearing in A. nidulans strain A28 only at 30‡C (lane 3) is sterol
glucoside. Lane 7, putative GlcCer puri¢ed from A. nidulans, 37‡C
culture.
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methods [7,21]. For the present work it was therefore su⁄-
cient to obtain 1-D 1H-NMR spectra of putative A. nidulans
GlcCer fractions under identical conditions in order to con-
¢rm their structures, except for the absolute lengths of the
ceramide alkyl/acyl chains. The representative spectrum in
Fig. 2A, obtained from the 37‡C A. nidulans cerebroside, ex-
hibits all seven 1H resonances characteristic of the L-glucopy-
ranosyl spin system, as well as resonances for key ceramide
features observed previously for fungal cerebrosides [7]. These
ceramide resonances indicate the presence of two predominant
ceramide types, consisting of [9,21] a (4E,8E)-9-methyl-4,8-
sphingadienine N-acylated with either 2P-hydroxyalkanoate
or 2P-hydroxy-(E)-3P-alkenoate. No resonances from GalCer
were detected in any A. nidulans cerebroside spectra.
In þESI-MS (Fig. 2B,C), abundant monolithiated molecu-
lar ion adducts were observed for both GlcCer fractions at
m/z 760 and m/z 762. These adduct masses are consistent with
GlcCer containing (d19:2) (4E,8E)-9-methyl-4,8-sphingadie-
nine attached to N-2P-hydroxy-(E)-3P-octadecenoate or N-2P-
hydroxyoctadecanoate, respectively. Interestingly, the consid-
erable predominance of the low m/z component at 30‡C (Fig.
2B) is reversed at 37‡C (Fig. 2C). In product ion spectra
obtained from the lithiated molecular ions (m/z 760 or m/z
762) by tandem þESI-MS/collision-induced dissociation-MS
(not shown), the masses and relative abundances of all frag-
ments were in each case virtually identical with those obtained
previously for GlcCer with the proposed ceramides di¡ering
only in the absence or presence of (E)-3P-unsaturation [8,21].
3.3. E¡ects of GCS inhibitors on growth and morphology of
A. nidulans and A. fumigatus
The e¡ects of GCS inhibitors were initially characterized by
observation of germination and subsequent hyphal growth of
A. nidulans and A. fumigatus spores in the presence or absence
of several PDMP analogs. When the round, asexual spores
(conidia) are introduced into nutrient medium, they break
dormancy and begin to grow isotropically, adding new mate-
rial uniformly to the cell periphery. After a de¢ned period of
time (5 h under our conditions), polar growth is established
with new material being added to only one region of the cell
surface. The result is the emergence of a germ tube and tip
elongation typical of ¢lamentous fungi. PDMP analogs were
Fig. 2. Structural characterization of A. nidulans cerebrosides. A: Down¢eld section of 1-D 1H-NMR spectrum (DMSO-d6/2% D2O, 35‡C) of
CMH isolated from A. nidulans cultured at 37‡C. Resonances from non-exchangeable protons of sphingosine (Sph), fatty acyl (Fa), and hexose
(pre¢x omitted) are designated by arabic numerals. Two locations each are shown for Sph-1a,1b to Sph-5 and Fa-2, corresponding to compo-
nents having saturated or (E)-3P-unsaturated 2-hydroxy fatty acid. B,C: þESI-MS molecular ion pro¢les of CMH (as Liþ adducts) isolated
from A. nidulans mycelia cultured at 30‡C and 37‡C, respectively.
FEBS 26342 31-7-02
S.B. Levery et al./FEBS Letters 525 (2002) 59^64 61
added to conidia after 5 h of incubation, at the point where
they typically have become fully swollen and begin to grow
asymmetrically as germ tube growth is initiated [23]. Incuba-
tion was continued for 5 more hours prior to ¢xing and stain-
ing, which is su⁄cient for extensive hyphal elongation, as
shown for the controls in Fig. 3A,C. Addition of PDMP or
PPMP at 20 WM had no detectable e¡ect on either species (not
shown). On the other hand, addition of EDO-P4 at 20 WM to
A. nidulans conidia halted growth just after germ tube emer-
gence (Fig. 3B).
We considered that the ability of A. fumigatus to synthesize
an alternative cerebroside (GalCer) might ameliorate the e¡ect
of GCS inhibitors. However, compared with the control, ad-
dition of P4 at 20 WM still severely limited growth of hyphae,
with most cells arresting growth just after polarity establish-
ment (Fig. 3D). Addition of EDO-P4 at 20 WM halted growth
before germ tube emergence (Fig. 3E). Although these results
are from experiments carried out at 37‡C, similar observations
were made for both species at 30‡C.
Addition of P4 or EDO-P4 to either species at a lower
concentration (4 WM) resulted in macroscopically normal
growth, but microscopic examination revealed nuclear abnor-
malities. As shown for A. fumigatus in Fig. 3F, many nuclei
appeared globular and of variable sizes relative to controls.
Even in cells where nuclei looked normal, there appeared to
be a higher number of mitotic nuclei. The mitotic index rose
from 4% in untreated A. fumigatus controls to 28^34% in
cultures treated with 4 WM P4 or EDO-P4. Thus, in addition
to observed morphological e¡ects, PDMP analogs might af-
fect DNA replication and segregation.
In the preceding experiments, inhibitor was added after
spores had broken dormancy and completed most of their
isotropic growth phase. To determine if PDMP analogs are
also e¡ective at other points in the early growth of A. fumi-
gatus, 40 WM EDO-P4 was added to cultures at de¢ned time
points during incubation, beginning with t=0. All cultures
were ¢xed and stained at the same end point, t=10 h. In
parallel, untreated control samples were ¢xed and stained at
each time point, re£ecting the normal morphological states
observable during early fungal growth. As shown in Fig. 4,
cells which were incubated after addition of EDO-P4 for suf-
¢cient time to exhibit extensive hyphal growth appeared iden-
tical to untreated controls which were ¢xed at the time of
inhibitor addition. Thus, the arrest of early fungal growth
by EDO-P4 is not stage-speci¢c.
3.4. Minimal inhibitory concentration experiments
To determine if A. fumigatus and A. nidulans were able to
recover from drug-induced growth arrest, a colony forming
assay was performed. Spores of A. fumigatus or A. nidulans
were treated with inhibitor, washed, plated to solid medium
and incubated for 2 days. The concentration of P4 or EDO-P4
was varied to provide a dose-dependent measure of response.
As shown in Fig. 5, a large percentage of spores were viable at
an inhibitor concentration of 0.4 WM, but virtually none were
viable after treatment with inhibitor at 40 WM. From these
results it is estimated that the IC50 in this assay for EDO-P4 is
1^2 WM, while that for P4 is 0.5^1 WM.
3.5. E¡ects of GCS inhibitors on GlcCer/GalCer expression in
A. fumigatus
In order to verify that GCS inhibitors developed for the
mammalian enzyme could also a¡ect GlcCer synthesis in fun-
gi, lipids were extracted from fungal cells grown in the pres-
ence or absence of sublethal doses of inhibitors, and analyzed
by HPTLC. Growth in the presence of inhibitors was accom-
plished by inoculation with a higher spore load than employed
in the coverslip assay (by a factor s 103 per ml), and delaying
the addition of drug until germ tube extension was well under
way. The experiment was performed with A. fumigatus, as its
ability to synthesize GalCer as well allowed the e¡ects of in-
hibition to be observed more easily via alteration of the ratio
of the two cerebroside components.
Fig. 3. E¡ect of GCS inhibitors on early growth of A. nidulans and
A. fumigatus. Conidia were inoculated to rich medium, inhibitor
was added after 5 h incubation at 37‡C, and incubation continued
for 5 h more prior to ¢xing and staining with Calco£uor white and
Hoechst 33258 to visualize cell walls and nuclei, respectively. A. ni-
dulans : A: no inhibitor; B: EDO-P4, 20 WM. A. fumigatus : C: no
inhibitor; D: P4, 20 WM; E: EDO-P4, 20 WM; F: EDO-P4, 4WM.
Insets, enlargement of nuclei to illustrate nuclear morphology. Left
column, DIC image; right column, £uorescence image. Scale
bars = 10 Wm.
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Compared with the control grown without inhibitor, myce-
lia grown in the presence of 20 WM P4 and EDO-P4 clearly
exhibited an increase in the amounts of GalCer compared
with GlcCer (Fig. 6, lanes 4 and 6). P4 at 4 WM also appeared
to have some e¡ect (lane 3). Although these HPTLC pro¢les
are semi-quantitative, at least in the case of 20 WM EDO-P4
the increase in staining of GalCer is clearly accompanied by a
concomitant decrease in staining of GlcCer (lane 6). PDMP
and PPMP appeared to have little or no e¡ect on the amount
of GalCer expressed (lanes 1 and 2, respectively).
4. Discussion
With only a few exceptions ^ notably the common labora-
tory strains of S. cerevisiae and Schizosaccharomyces pombe ^
the biosynthetic machinery for GlcCer expression appears to
be universally distributed among fungi [1,8,10,21,24] (and
references cited therein). Genes encoding proteins exhibiting
signi¢cant homology to mammalian GCSs can be found in
several fungal genomic databases, including those of Candida
albicans and Neurospora crassa. Although the identities in
peptide sequence alignments are low (16^21% for C. albicans,
Magnaporthe grisea, and Pichia pastoris compared to human)
[10], the similarities increase considerably if conservative sub-
stitutions are included. In any case, the biosynthetic functions
of the C. albicans, M. grisea, and P. pastoris homologs were
recently demonstrated by cloning and expression in S. cerevi-
Fig. 4. E¡ect of GCS inhibitor EDO-P4 on A. fumigatus growth. A. fumigatus conidia were inoculated to rich medium, 40 WM EDO-P4 was
added at de¢ned time points, cells were incubated until t=10 h, ¢xed and stained with Calco£uor white and Hoechst 33258 to visualize cell
walls and nuclei, respectively. Controls were ¢xed at time of drug addition. A^C: Untreated control; D^F: EDO-P4 treated; A and C: 0 h;
B and E: 4 h; C and F: 7 h.
Fig. 5. Colony forming assay on A. fumigatus conidia treated with
P4 and EDO-P4. Conidia were treated with inhibitors at 40, 4, and
0.4 WM, washed thoroughly, and replated on solid agar medium.
Number of colony forming units after 48 h incubation relative to
untreated controls is shown.
Fig. 6. E¡ects of GCS inhibitors on relative levels of GlcCer and
GalCer expression in A. fumigatus. Shown is lower section of orci-
nol-stained analytical HPTLC plate comparing crude neutral lipids
extracted from A. fumigatus strain 9197 cultured at 37‡C grown in
the absence of inhibitor (lane C, control), and in the presence of
PDMP at 20 WM (lane 1), PPMP at 20 WM (lane 2), P4 at 4 and
20 WM (lanes 3 and 4, respectively), and EDO-P4 at 4 and 20 WM
(lanes 5 and 6, respectively). Amounts streaked were normalized by
adjusting the dilution with respect to wet weight yields of mycelia
extracted (125 Wl solvent per g mycelium; 10 Wl per lane). Note that
two pairs of lanes, 3 and 4, 5 and 6, have been digitally ‘£ipped’
with respect to the original plate.
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siae or in a GCS null mutant generated from P. pastoris [10] ;
successful expression was veri¢ed by isolation and character-
ization of authentic GlcCer products from the previously null
yeast strains.
While isolation and analysis of GlcCer from fungi is
straightforward, direct assays of GCS activities [25,26] have
so far failed in our hands to work with fungal membrane
extracts. As far as we are aware, no successful adaptation of
a GCS assay to a fungal homolog has been reported. Similar
to Leipelt et al. [10], we therefore relied on direct analysis of
the cerebroside products from A. fumigatus grown in the pres-
ence or absence of sublethal amounts of inhibitors as evidence
for their e¡ects on GlcCer biosynthesis. These experiments
clearly showed buildup of GalCer in the presence of P4 and
EDO-P4, consistent with inhibition of a GCS that is compet-
ing for the same pool of ceramide acceptor substrate. The
most striking quantitative di¡erences correlated with inhibi-
tors having the greatest potency and speci¢city toward the
mammalian enzyme [16,17], and these in turn correlated
with the most dramatic e¡ects observed in the biological as-
says. Too little is known at this time to assume that no other
enzymes are directly a¡ected by these compounds in fungi,
but the observed trends are consistent with the designed and
well-tested properties of P4 and EDO-P4, having GCS as their
sole target [16,17].
Interestingly, the susceptibility of A. fumigatus appears to
be similar to that of A. nidulans, which does not produce
GalCer. The e¡ects of P4 and EDO-P4 on A. fumigatus and
A. nidulans suggest that such inhibitors of GCS will be useful
tools for analyzing the physiological function(s) of GlcCer
and GlcCer synthase in fungi. In addition, as has already
proved the case with inositol phosphorylceramide synthases
[27], GCSs might provide an important target for develop-
ment of new classes of antifungal agents, especially as their
structure(s) and function(s) become better understood. While
the IC50 for EDO-P4 observed against A. fumigatus is V10
times the concentration found e¡ective in assays with mam-
malian cells [17], this does not necessarily preclude GCS as a
potential target of antifungal therapeutics. The development
of PDMP analogs has been directed speci¢cally toward their
eventual use in humans for treatment of cancer and GSL
storage diseases, and increases in their speci¢city have been
accompanied by a signi¢cantly lowered toxicity toward mam-
malian cells [16,17]. Moreover, despite the sequence similar-
ities between the mammalian and fungal enzymes, there are
also signi¢cant di¡erences, which suggests that drugs may yet
be produced exhibiting much higher speci¢city for the latter.
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